Yusuke Furukawa

List of Publications by Year
in descending order

170	6,277	76196	79541
papers	citations	40 h-index	73 g-index

181	181	181	6949
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell, 1989, 58, 1085-1095.	13.5	942
2	In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood, 2001, 97, 1999-2007.	0.6	248
3	The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 1795-1798.	3.3	227
4	cdc2 gene expression at the G1 to S transition in human T lymphocytes. Science, 1990, 250, 805-808.	6.0	216
5	Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene, 2009, 28, 231-242.	2.6	171
6	Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and noncycling human hematopoietic cells.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 2770-2774.	3.3	137
7	Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood, 2010, 116, 406-417.	0.6	121
8	Apaf-1 Is a Mediator of E2F-1-induced Apoptosis. Journal of Biological Chemistry, 2002, 277, 39760-39768.	1.6	119
9	Phosphorylation of Bcl-2 Protein by CDC2 Kinase during G2/M Phases and Its Role in Cell Cycle Regulation. Journal of Biological Chemistry, 2000, 275, 21661-21667.	1.6	101
10	Treatment of myeloid leukemic cells with the phosphatase inhibitor okadaic acid induces cell cycle arrest at either G1/S or G2/M depending on dose. Journal of Cellular Physiology, 1992, 150, 484-492.	2.0	94
11	The Expression of ST2 Gene in Helper T Cells and the Binding of ST2 Protein to Myeloma-Derived RPMI8226 Cells. Journal of Biochemistry, 1997, 121, 95-103.	0.9	94
12	Ablation of Neutral Cholesterol Ester Hydrolase 1 Accelerates Atherosclerosis. Cell Metabolism, 2009, 10, 219-228.	7.2	93
13	Lineage-specific regulation of cell cycle control gene expression during haematopoietic cell differentiation. British Journal of Haematology, 2000, 110, 663-673.	1.2	87
14	HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia, 2010, 24, 1760-1768.	3.3	86
15	Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma. Journal of Clinical Investigation, 2015, 125, 4375-4390.	3.9	85
16	Transcriptional Modulation Using HDACi Depsipeptide Promotes Immune Cell-Mediated Tumor Destruction of Murine B16 Melanoma. Journal of Investigative Dermatology, 2008, 128, 1506-1516.	0.3	84
17	Fanconi anemia protein, FANCA, associates with BRG1, a component of the human SWI/SNF complex. Human Molecular Genetics, 2001, 10, 2651-2660.	1.4	81
18	Direct Transcriptional Activation of Human Caspase-1 by Tumor Suppressor p53. Journal of Biological Chemistry, 2001, 276, 10585-10588.	1.6	80

#	Article	IF	Citations
19	Methylation Silencing of the Apaf-1 Gene in Acute Leukemia. Molecular Cancer Research, 2005, 3, 325-334.	1.5	78
20	A novel I-branching Î²-1,6-N-acetylglucosaminyltransferase involved in human blood group I antigen expression. Blood, 2003, 101, 2870-2876.	0.6	77
21	Promoter methylation confers kidneyâ€specific expression of the Klotho gene. FASEB Journal, 2012, 26, 4264-4274.	0.2	75
22	Polyploidization and Functional Maturation Are Two Distinct Processes During Megakaryocytic Differentiation: Involvement of Cyclin-Dependent Kinase Inhibitor p21 in Polyploidization. Blood, 1997, 89, 3980-3990.	0.6	71
23	Histone deacetylase 1 enhances microRNA processing via deacetylation of DGCR8. EMBO Reports, 2012, 13, 142-149.	2.0	71
24	Expression Levels of Histone Deacetylases Determine the Cell Fate of Hematopoietic Progenitors. Journal of Biological Chemistry, 2009, 284, 30673-30683.	1.6	68
25	Human Monocyteâ€“Endothelial Cell Interaction Induces Synthesis of Granulocyte-Macrophage Colony-Stimulating Factor. Circulation, 1996, 93, 1185-1193.	1.6	61
26	Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Molecular Cancer Research, 2003, 1, 940-7.	1.5	60
27	Transcriptional Activation of the cdc2 Gene Is Associated with Fas-induced Apoptosis of Human Hematopoietic Cells. Journal of Biological Chemistry, 1996, 271, 28469-28477.	1.6	59
28	Downregulation of an Aim-1 Kinase Couples with Megakaryocytic Polyploidization of Human Hematopoietic Cells. Journal of Cell Biology, 2001, 152, 275-288.	2.3	58
29	Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia. Leukemia, 2014, 28, 1216-1226.	3.3	55
30	Histone deacetylase inhibitor FK228 suppresses the Rasâ€“MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma. Oncogene, 2006, 25, 512-524.	2.6	53
31	Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines. Leukemia, 2007, 21, 1005-1014.	3.3	53
32	Molecular pathogenesis of multiple myeloma. International Journal of Clinical Oncology, 2015, 20, 413-422.	1.0	52
33	A Janus Kinase Inhibitor, JAB, Is an Interferon-Î³â€“Inducible Gene and Confers Resistance to Interferons. Blood, 1998, 92, 1668-1676.	0.6	52
34	Apoptosis during HL-60 cell differentiation is closely related to a G0/G1 cell cycle arrest. Journal of Cellular Physiology, 1995, 164, 74-84.	2.0	51
35	Histone Deacetylase Inhibitor Depsipeptide (FK228) Induces Apoptosis in Leukemic Cells by Facilitating Mitochondrial Translocation of Bax, Which Is Enhanced by the Proteasome Inhibitor Bortezomib. Acta Haematologica, 2006, 115, 78-90.	0.7	48
36	Overexpression of the shortest isoform of histone demethylase LSD1 primes hematopoietic stem cells for malignant transformation. Blood, 2015, 125, 3731-3746.	0.6	47

#	Article	IF	Citations
37	Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7. Leukemia, 2020, 34, 180-195.	3.3	47
38	Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines. Investigational New Drugs, 2006, 25, 31-40.	1.2	46
39	Induction of Ubiquitin-Conjugating Enzyme by Aggregated Low Density Lipoprotein in Human Macrophages and Its Implications for Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 128-134.	1.1	45
40	Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma. International Journal of Hematology, 2016, 104, 281-292.	0.7	44
41	Transcriptional repression of the E2F-1 gene by interferon-Î± is mediated through induction of E2F-4/pRB and E2F-4/p130 complexes. Oncogene, 1999, 18, 2003-2014.	2.6	43
42	Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228). Journal of Cellular Physiology, 2005, 203, 387-397.	2.0	42
43	Molecular basis of clonal evolution in multiple myeloma. International Journal of Hematology, 2020, 111, 496-511.	0.7	42
44	Human monocyte-endothelial cell interaction induces platelet-derived growth factor expression. Cardiovascular Research, 1998, 37, 216-224.	1.8	41
45	Cell Cycle Control Genes and Hematopoietic Cell Differentiation. Leukemia and Lymphoma, 2002, 43, 225-231.	0.6	41
46	Modulation of E2F Activity Is Linked to Interferon-induced Growth Suppression of Hematopoietic Cells. Journal of Biological Chemistry, 1997, 272, 12406-12414.	1.6	39
47	Vasoactive Intestinal Peptide Regulates its Receptor Expression and Functions of Human Keratinocytes via Type I Vasoactive Intestinal Peptide Receptors. Journal of Investigative Dermatology, 2001, 116, 743-749.	0.3	39
48	Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cells. Journal of Immunology, 1989, 143, 3543-7.	0.4	37
49	Soluble Î±Klotho as a candidate for the biomarker of aging. Biochemical and Biophysical Research Communications, 2015, 467, 1019-1025.	1.0	36
50	Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19). Blood, 2010, 116, 962-970.	0.6	35
51	Single Glycosyltransferase, Core 2 Î²1â†'6-N-acetylglucosaminyltransferase, Regulates Cell Surface Sialyl-Lex Expression Level in Human Pre-B Lymphocytic Leukemia Cell Line KM3 Treated with Phorbolester. Journal of Biological Chemistry, 1998, 273, 26779-26789.	1.6	33
52	Establishment and characterization of four human monocytoid leukemia cell lines (JOSK-I, -S, -M and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf interleukin 1. Cancer Research, 1986, 46, 3067-74.	0.4	33
53	Cell cycle regulation of hematopoietic stem cells. Human Cell, 1998, 11, 81-92.	1.2	33
54	Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines. PLoS ONE, 2017, 12, e0188680.	1.1	32

#	Article	IF	Citations
55	Alterations of Common Chromosome Fragile Sites in Hematopoietic Malignancies. International Journal of Hematology, 2004, 79, 238-242.	0.7	31
56	In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis. Leukemia, 2000, 14, 379-388.	3.3	30
57	Suppression of ARG kinase activity by STI571 induces cell cycle arrest through up-regulation of CDK inhibitor p18/INK4c. Oncogene, 2003, 22, 4074-4082.	2.6	30
58	CD43, but not P-Selectin Glycoprotein Ligand-1, Functions as an E-Selectin Counter-Receptor in Human Pre-Bâ€“Cell Leukemia NALL-1. Cancer Research, 2008, 68, 790-799.	0.4	30
59	Tenascin-X expression in tumor cells and fibroblasts: glucocorticoids as negative regulators in fibroblasts. Journal of Cell Science, 1996, 109, 2069-2077.	1.2	29
60	Interleukin-1 producing ability of leukaemia cells and its relationship to morphological diagnosis. British Journal of Haematology, 1987, 65, 11-15.	1.2	28
61	Stimulation of GATA-2 as a mechanism of hydrogen peroxide suppression in hypoxia-induced erythropoietin gene expression. Journal of Cellular Physiology, 2001, 186, 260-267.	2.0	28
62	Arf tumor suppressor disrupts the oncogenic positive feedback loop including c-Myc and DDX5. Oncogene, 2015, 34, 314-322.	2.6	28
63	Hyperglycemia enhances VSMC proliferation with NF-Î¹B activation by angiotensin II and E2F-1 augmentation by growth factors. Molecular and Cellular Endocrinology, 2002, 192, 75-84.	1.6	27
64	The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations. Oncogene, 2008, 27, 3102-3110.	2.6	27
65	Heterogeneous expression of the product of the retinoblastoma susceptibility gene in primary human leukemia cells. Oncogene, 1991, 6, 1343-6.	2.6	27
66	Expression of Differentiation-Related Phenotypes and Apoptosis Are Independently Regulated during Myeloid Cell Differentiation1. Journal of Biochemistry, 1995, 117, 77-84.	0.9	25
67	E2F-6 Suppresses Growth-Associated Apoptosis of Human Hematopoietic Progenitor Cells by Counteracting Proapoptotic Activity of E2F-1. Stem Cells, 2007, 25, 2439-2447.	1.4	25
68	Purine Analog-Like Properties of Bendamustine Underlie Rapid Activation of DNA Damage Response and Synergistic Effects with Pyrimidine Analogues in Lymphoid Malignancies. PLoS ONE, 2014, 9, e90675.	1.1	25
69	Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect. Anticancer Research, 2004, 24, 2705-12.	0.5	24
70	Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro. Leukemia, 2002, 16, 1808-1817.	3.3	23
71	Alteration of the fragile histidine triad gene early in carcinogenesis: an update. Journal of Experimental Therapeutics and Oncology, 2003, 3, 291-296.	0.5	23
72	Frag1, a homolog of alternative replication factor C subunits, links replication stress surveillance with apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9655-9660.	3.3	23

#	Article	IF	Citations
73	Vinculin Is Indispensable for Repopulation by Hematopoietic Stem Cells, Independent of Integrin Function. Journal of Biological Chemistry, 2010, 285, 31763-31773.	1.6	23
74	The Novel Orally Active Proteasome Inhibitor K-7174 Exerts Anti-myeloma Activity in Vitro and in Vivo by Down-regulating the Expression of Class I Histone Deacetylases. Journal of Biological Chemistry, 2013, 288, 25593-25602.	1.6	23
75	Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosomeâ€“Positive Lymphoid Leukemia. Molecular Cancer Therapeutics, 2016, 15, 94-105.	1.9	23
76	Myeloma Cells Are Activated in Bone Marrow Microenvironment by the CD180/MD-1 Complex, Which Senses Lipopolysaccharide. Cancer Research, 2018, 78, 1766-1778.	0.4	23
77	Components of DNA Damage Checkpoint Pathway Regulate UV Exposureâ€“Dependent Alterations of Gene Expression of FHIT and WWOX at Chromosome Fragile Sites. Molecular Cancer Research, 2005, 3, 130-138.	1.5	22
78	Interferon-Î± repressed telomerase along with G1-accumulation of Daudi cells. Cancer Letters, 1999, 142, 23-30.	3.2	21
79	Identification of Novel p53-Binding Proteins by Biomolecular Interaction Analysis Combined with Tandem Mass Spectrometry. Molecular Biotechnology, 2003, 23, 203-212.	1.3	21
80	Transactivation of RON receptor tyrosine kinase by interaction with PDGF receptor Î² during steady-state growth of human mesangial cells. Kidney International, 2009, 75, 1173-1183.	2.6	21
81	Vasoactive intestinal peptide and inflammatory cytokines enhance vascular endothelial growth factor production from epidermal keratinocytes. British Journal of Dermatology, 2009, 161, 1232-1238.	1.4	21
82	Tenascin-C induction by the diffusible factor epidermal growth factor in stromal-epithelial interactions. Journal of Cellular Physiology, 1995, 165, 18-29.	2.0	20
83	Latexin regulates the abundance of multiple cellular proteins in hematopoietic stem cells. Journal of Cellular Physiology, 2012, 227, 1138-1147.	2.0	20
84	Preferential Production of Interleukin-1Î² over Interleukin-1 Receptor Antagonist Contributes to Proliferation and Suppression of Apoptosis in Leukemic Cells. Japanese Journal of Cancer Research, 1995, 86, 208-216.	1.7	19
85	Tyrosine kinase inhibitors reduce bcl-2 expression and induce apoptosis in androgen-dependent cells. American Journal of Physiology - Cell Physiology, 2000, 278, C66-C72.	2.1	19
86	Modulation of the erythropoietin-induced proliferative pathway by cAMP in vascular smooth muscle cells. American Journal of Physiology - Cell Physiology, 2002, 283, C1715-C1721.	2.1	19
87	Inactivation of ERK accelerates erythroid differentiation of K562 cells induced by herbimycin A and STI571 while activation of MEK1 interferes with it. Molecular and Cellular Biochemistry, 2004, 258, 25-33.	1.4	18
88	Cell cycle control during hematopoietic cell differentiation. Human Cell, 1997, 10, 159-64.	1.2	18
89	Cell-Cycleâ€“Dependent Regulation of Erythropoietin Receptor Gene. Blood, 1997, 89, 1182-1188.	0.6	17
90	Rad9 modulates the P21WAF1 pathway by direct association with p53. BMC Molecular Biology, 2007, 8, 37.	3.0	17

#	Article	IF	Citations
91	Eradication of Central Nervous System Leukemia of T-Cell Origin with a Brain-Permeable LSD1 Inhibitor. Clinical Cancer Research, 2019, 25, 1601-1611.	3.2	17
92	Cytomegalovirus Gastritis as an Initial Manifestation of a Patient with Adult T-Cell Leukemia. Acta Haematologica, 1988, 80, 216-218.	0.7	16
93	Regulatory effects of aggregated LDL on apoptosis during foam cell formation of human peripheral blood monocytes. FEBS Letters, 1997, 409, 177-182.	1.3	16
94	MSK1 activation in acute myeloid leukemia cells with FLT3 mutations. Leukemia, 2010, 24, 1087-1090.	3.3	16
95	Schedule-Dependent Interactions Between Pemetrexed and Cisplatin in Human Carcinoma Cell Lines In Vitro. Oncology Research, 2006, 16, 85-95.	0.6	16
96	Phosphorylation of Fanconi Anemia Protein, FANCA, Is Regulated by Akt Kinase. Biochemical and Biophysical Research Communications, 2002, 291, 628-634.	1.0	15
97	Ectopic cyclin D1 expression blocks STI571-induced erythroid differentiation of K562 cells. Leukemia Research, 2004, 28, 623-629.	0.4	15
98	Up-regulation of Survivin by the E2A-HLF Chimera Is Indispensable for the Survival of t(17;19)-positive Leukemia Cells. Journal of Biological Chemistry, 2010, 285, 1850-1860.	1.6	15
99	Reduced Histone H3K9 Acetylation of Clock Genes and Abnormal Glucose Metabolism in ob/ob Mice. Chronobiology International, 2012, 29, 982-993.	0.9	15
100	A novel variant of acute myelomonocytic leukemia carrying t(3;12)(q26;p13) with characteristics of 3q21q26 syndrome. International Journal of Hematology, 1998, 67, 361.	0.7	15
101	Defective binding of IRFs to the initiator element of interleukin-1Î²-converting enzyme (ICE) promoter in an interferon-resistant Daudi subline. FEBS Letters, 1999, 450, 263-267.	1.3	14
102	Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro. Cancer Chemotherapy and Pharmacology, 2004, 54, 505-513.	1.1	14
103	Homopiperazine Derivatives as a Novel Class of Proteasome Inhibitors with a Unique Mode of Proteasome Binding. PLoS ONE, 2013, 8, e60649.	1.1	14
104	Serum Endocrine Fibroblast Growth Factors as Potential Biomarkers for Chronic Kidney Disease and Various Metabolic Dysfunctions in Aged Patients. Internal Medicine, 2020, 59, 345-355.	0.3	14
105	Herbimycin A down-regulates messages of cyclin D1 and c-myc during erythroid differentiation of K562 cells. International Journal of Hematology, 1996, 65, 31.	0.7	14
106	Lysine-specific demethylase 1 inhibitors prevent teratoma development from human induced pluripotent stem cells. Oncotarget, 2018, 9, 6450-6462.	0.8	14
107	Cancer Prevention and Therapy in a Preclinical Mouse Model: Impact of FHIT Viruses. Current Gene Therapy, 2004, 4, 53-63.	0.9	13
108	Alkylating agents induce histone H3K18 hyperacetylation and potentiate HDAC inhibitor-mediated global histone acetylation and cytotoxicity in mantle cell lymphoma. Blood Cancer Journal, 2013, 3, e169-e169.	2.8	12

#	Article	IF	Citations
109	Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells. International Journal of Hematology, 2014, 99, 726-736.	0.7	12
110	The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro. Anticancer Research, 2009, 29, 4589-96.	0.5	12
111	Vasoactive Intestinal Peptide and Cytokines Enhance Stem Cell Factor Production From Epidermal Keratinocytes DJM-1. Journal of Investigative Dermatology, 2002, 119, 1183-1188.	0.3	11
112	Regulation of EGF-induced tenascin-C by steroids in tenascin-C-non-producing human carcinoma cells. International Journal of Cancer, 1995, 63, 720-725.	2.3	9
113	Tenascin-C Induction in Whitlock-Witte Culture: A Relevant Role of the Thiol Moiety in Lymphoid-Lineage Differentiation. Experimental Cell Research, 1995, 217, 395-403.	1.2	9
114	UDP-GlcNAc:GalÂ1->3GalNAc (GlcNAc to GalNAc) Â1->6N-acetylglucosaminyltransferase holds a key role on the control of CD15s expression in human pre-B lymphoid cell lines. Glycobiology, 1999, 9, 1-12.	1.3	9
115	Simultaneous core 2 Î²1â†'6N-acetylglucosaminyltransferase up-regulation and sialyl-LeXexpression during activation of human tonsillar B lymphocytes. FEBS Letters, 1999, 463, 125-128.	1.3	9
116	Effect of exogenous E2F-1 on the expression of common chromosome fragile site genes, FHIT and WWOX. Biochemical and Biophysical Research Communications, 2004, 316, 1088-1093.	1.0	9
117	Myeloid and erythroid lineage expression of haemopoietic progenitors derived from an abnormal clone in erythroleukaemia. British Journal of Haematology, 1986, 64, 647-656.	1.2	8
118	Interleukin-1 derived from human monocytic leukemia cell line JOSK-I acts as an autocrine growth factor. Biochemical and Biophysical Research Communications, 1987, 147, 39-46.	1.0	8
119	Over-expression and amplification of the CDC2 gene in leukaemia cells. British Journal of Haematology, 1995, 90, 94-99.	1.2	8
120	Rapid internalization of exogenous ganglioside GM3 and its metabolism to ceramide in human myelogenous leukemia HL-60 cells compared with control ganglioside GM1. FEBS Letters, 1997, 400, 350-354.	1.3	8
121	Transcriptional repressor E2F-6 regulates apoptosis of hematopoietic stem cells. Experimental Hematology, 2000, 28, 1504-1505.	0.2	8
122	Differentially expressed genes execute zinc-induced apoptosis in precancerous esophageal epithelium of zinc-deficient rats. Oncogene, 2004, 23, 8040-8048.	2.6	8
123	Ras-mediated Up-regulation of Survivin Expression in Cytokine-dependent Murine Pro-B Lymphocytic Cells. Tohoku Journal of Experimental Medicine, 2008, 216, 25-34.	0.5	8
124	A novel missense mutation of ABCA1 in transmembrane Î±-helix in a Japanese patient with Tangier disease. Atherosclerosis, 2009, 206, 216-222.	0.4	8
125	AMPâ€activated protein kinase activation primes cytoplasmic translocation and autophagic degradation of the BCRâ€ABL protein in CML cells. Cancer Science, 2021, 112, 194-204.	1.7	8
126	Three-dimensional matrix suppresses E2F-controlled gene expression in glomerular mesangial cells. Kidney International, 2000, 57, 1581-1589.	2.6	7

#	Article	IF	Citations
127	Differences in E2F subunit expression in quiescent and proliferating vascular smooth muscle cells. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H204-H212.	1.5	7
128	Role of cyclins in cAMP inhibition of glomerular mesangial cell proliferation. Clinical Science, 2004, 107, 81-87.	1.8	7
129	Cholesterol Reduction and Atherosclerosis Inhibition by Bezafibrate in Low-Density Lipoprotein Receptor Knockout Mice. Hypertension Research, 2008, 31, 999-1005.	1.5	7
130	BCR-ABL regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome-positive leukemia. Oncogene, 2013, 32, 1670-1681.	2.6	7
131	Romidepsin Overcomes Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma Cells. Acta Haematologica, 2014, 132, 1-4.	0.7	7
132	Soluble SLAMF7 is a predictive biomarker for elotuzumab therapy. Leukemia, 2020, 34, 3088-3090.	3.3	7
133	Antileukemic effect of nitrous oxide in a patient with chronic myelogenous leukemia. American Journal of Hematology, 1989, 30, 114-114.	2.0	6
134	Interleukin 1 production by monocytic leukemia cells and its possible role in coagulation abnormalities. Leukemia Research, 1991, 15, 1133-1137.	0.4	6
135	Combination chemotherapy of carboplatin and cytosine arabinoside for high-risk leukemia: A pilot study. Leukemia Research, 1995, 19, 899-903.	0.4	6
136	Interleukin-3-associated ganglioside GD1a is induced independently of normal interleukin-3 receptor in murine myelogenous leukaemia NFS60 cells transfected with the interleukin-3 gene. Glycoconjugate Journal, 1996, 13, 255-261.	1.4	6
137	mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3-and Blimp-1-mediated BCL-2 up-regulation. Haematologica, 2021, 106, 3008-3013.	1.7	6
138	Splicing- and demethylase-independent functions of LSD1 in zebrafish primitive hematopoiesis. Scientific Reports, 2020, 10, 8521.	1.6	6
139	Schedule-Dependent Interaction Between Raltitrexed and 5-Fluorouracil in Human Colon Cancer Cell Lines In Vitro. Oncology Research, 2001, 12, 137-148.	0.6	5
140	Regulation of macrophage-specific gene expression by degenerated lipoproteins. Electrophoresis, 2000, 21, 338-346.	1.3	4
141	Schedule-dependent Synergism and Antagonism between Raltitrexed (â€œTomudexâ€) and Methotrexate in Human Colon Cancer Cell Linesin vitro. Japanese Journal of Cancer Research, 2001, 92, 74-82.	1.7	4
142	Differential Roles of E-Type Cyclins During Transformation of Murine E2F-1â€“Deficient Cells. DNA and Cell Biology, 2005, 24, 173-179.	0.9	4
143	Activation of Focal Adhesion Kinase in Detached Human Epidermal Cancer Cells and Their Long-term Survival Might be Associated with Cell Surface Expression of Laminin-5. Acta Dermato-Venereologica, 2008, 88, 100-107.	0.6	4
144	Schedule-dependent synergism and antagonism between pemetrexed and docetaxel in human lung cancer cell lines in vitro. Cancer Chemotherapy and Pharmacology, 2009, 64, 1129-1137.	1.1	4

#	Article	IF	Citations
145	Conversion of human fibroblasts into multipotent cells by cell-penetrating peptides. Biochemical and Biophysical Research Communications, 2019, 518, 134-140.	1.0	4
146	Failure of cdc2 promoter activation and G2/M transition by ANG II and AVP in vascular smooth muscle cells. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 277, H515-H523.	1.5	3
147	A Simple Semisolid Subtraction Method Using Carbodiimide-Coated Microplates. Molecular Biotechnology, 2000, 15, 193-200.	1.3	3
148	Bone marrow stromal cell-mediated degradation of CD20 leads to primary rituximab resistance in mantle cell lymphoma. Leukemia, 2021, 35, 1506-1510.	3.3	3
149	Long-Term Results of Dose-Intensive Chemotherapy With G-CSF Support (TCC-NHL-91) for Advanced Intermediate-Grade Non-Hodgkin's Lymphoma: A Review of 59 Consecutive Cases Treated at a Single Institute. Oncology Research, 2008, 17, 137-149.	0.6	3
150	Identification of characteristic proteins at late-stage erythroid differentiation in vitro. Human Cell, 2021, 34, 745-749.	1.2	2
151	Bortezomib Overcomes Cell Adhesion-Mediated Drug Resistance Via Down-Regulation of VLA-4 Expression in Multiple Myeloma.. Blood, 2008, 112, 1634-1634.	0.6	2
152	Biosynthesis of the So-Called "a" and "Asialo" Pathway Glycosphingolipids Is Differentially Regulated in Murine Myelogenous Leukemia NFS60 Cells. Biochemical and Biophysical Research Communications, 1995, 217, 733-740.	1.0	1
153	Kinetics of cytokine receptor internalization under steady-state conditions affects growth of neighboring blood cells. Haematologica, 2020, 105, e325-e327.	1.7	1
154	Autophagic degradation of NOXA underlies stromal cell-mediated resistance to proteasome inhibitors in mantle cell lymphoma. Leukemia Research, 2021, 111, 106672.	0.4	1
155	K15 promoter-driven enforced expression of NKIRAS exhibits tumor suppressive activity against the development of DMBA/TPA-induced skin tumors. Scientific Reports, 2021, 11, 20658.	1.6	1
156	THE ROLE OF RAD9 IN HEAD AND NECK CANCER. Japanese Journal of Head and Neck Cancer, 2006, 32, 417-422.	0.0	1
157	Ectopic Expression and Role of RCAN1 in Myeloid Leukemia Cells.. Blood, 2009, 114, 1274-1274.	0.6	1
158	A case of cytophagic histiocytic panniculitis. Japanese Journal of Clinical Immunology, 1986, 9, 58-64.	0.0	1
159	Inactivation of the Retinoblastoma Protein by Mutant B-Raf in Malignant Melanoma. Nature Precedings, 2010, , .	0.1	0
160	Overexpression of the shortest isoform of histone demethylase LSD1 primes hematopoietic stem/progenitor cells for malignant transformation. Experimental Hematology, 2015, 43, S63.	0.2	0
161	Histone deacetylases as novel therapeutic targets for refractory and relapsed multiple myeloma. Annals of Oncology, 2016, 27, vii31.	0.6	0
162	Cell adhesion-induced phosphorylation and inactivation of EZH2 confer drug resistance to acute myeloid leukemia cells. International Journal of Hematology, 2018, 107, 383-385.	0.7	0

#	Article	IF	Citations
163	Lysine-specific demethylase 1 accelerates oncogenesis in p53 heterozygous mice via transcriptional repression of the residual Trp53 allele. Leukemia Research, 2019, 82, 29-32.	0.4	0
164	Pivotal Role of Survivin in Leukemogenesis by E2A-HLF Chimeric Transcription Factor.. Blood, 2005, 106, 2988-2988.	0.6	0
165	The regulation of Rad9 for therapy of head and neck cancer. Japanese Journal of Head and Neck Cancer, 2007, 33, 425-428.	0.0	0
166	The expression of rad9 in head and neck cancer. Japanese Journal of Head and Neck Cancer, 2008, 34, 493-497.	0.0	0
167	BCR-ABL Regulates Death Receptor Expression for TNF-Related Apoptosis-Inducing Ligand (TRAIL) in Philadelphia Chromosome-Positive Leukemia. Blood, 2011, 118, 2740-2740.	0.6	0
168	A LONG-TERMSURVIVAL CASE OF HEPATIC METASTASIS OF RECTAL CARCINOID. The Journal of the Japanese Practical Surgeon Society, 1997, 58, 1079-1083.	0.0	0
169	Multiple Myeloma: bench to bedside.. Denki Eido, 2017, 61, 93-96.	0.0	0
170	Fast in-vitro screening of FLT3-ITD inhibitors using silkworm-baculovirus protein expression system. PLoS ONE, 2022, 17, e0261699.	1.1	0